GlassScriptPhysician profile
Yasmin B Khan
NPI 1891867297
$3,390.32
in general payments reported to CMS, 2019-2025
32 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $459 · 2021: $526 · 2022: $669 · 2023: $270 · 2024: $269 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709.74 | 2019-2024 | |
| Celularity INC. | $300.00 | 2019 | |
| Exeltis, USA INC. | $268.73 | 2019-2025 | Slynd |
| Avion Pharmaceuticals | $188.72 | 2019-2023 | Balcoltra |
| Organon LLC | $160.06 | 2021-2025 | Nexplanon |
| Millicent US INC | $157.52 | 2020-2025 | Intrarosa, Femlyv, Femring |
| Pfizer INC. | $148.12 | 2019-2022 | |
| Insulet Corporation | $139.00 | 2025 | Omnipod |
| Sumitomo Pharma America, INC. | $132.87 | 2023-2024 | Myfembree |
| Ascend Therapeutics US, LLC | $132.79 | 2019-2021 | |
| Therapeuticsmd, INC. | $115.38 | 2019-2022 | |
| Galderma Laboratories, L.P. | $111.98 | 2019 | |
| Lilly USA, LLC | $94.08 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $92.24 | 2022 | |
| Astellas Pharma US INC | $85.00 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $52.18 | 2019-2020 | |
| Allergan, INC. | $48.59 | 2019-2020 | |
| Myovant Sciences INC. | $43.95 | 2022 | |
| Hologic Sales and Service, LLC | $43.36 | 2019-2024 | Novasure, Omni Hysteroscope, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $42.07 | 2019-2020 | |
| Monaghan Medical Corporation | $35.53 | 2024 | Aerobika |
| Amag Pharmaceuticals, INC. | $33.56 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $33.05 | 2025 | |
| Ethicon US, LLC | $32.08 | 2023-2024 | Ethicon, Stratafix, Enseal X1 |
| Sage Therapeutics, LLC | $31.33 | 2025 | Zurzuvae |
| Duchesnay USA Incorporated | $27.50 | 2019 | |
| Northgate Technologies, INC. | $25.82 | 2024 | Stimsite |
| Merck Sharp & Dohme LLC | $25.65 | 2020-2021 | |
| Boston Scientific Corporation | $24.57 | 2025 | Rezum Generator |
| Evofem Biosciences, INC. | $22.71 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.36 | 2021 | |
| Zyla Life Sciences, INC. | $13.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmin Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.